血液中的 MALT1 反映了老年慢性阻塞性肺病患者的急性加重风险和炎症。

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2024-01-01 Epub Date: 2024-08-13 DOI:10.1080/17520363.2024.2347199

Cui Liu, Jinsong Zhu, Lei Zhao, Guanying Li, Jiawei Sun, Shengli Zhang, Xijun Liang

{"title":"血液中的 MALT1 反映了老年慢性阻塞性肺病患者的急性加重风险和炎症。","authors":"Cui Liu, Jinsong Zhu, Lei Zhao, Guanying Li, Jiawei Sun, Shengli Zhang, Xijun Liang","doi":"10.1080/17520363.2024.2347199","DOIUrl":null,"url":null,"abstract":"Aim: This study intended to investigate the ability of blood MALT1 to estimate acute exacerbation risk in elderly chronic obstructive pulmonary disease (COPD) patients.Methods: Blood MALT1 was detected in 176 elderly COPD patients (aged more than 60 years).Results: MALT1 was elevated in patients with COPD acute exacerbation versus patients with stable COPD (p < 0.001). In patients with COPD acute exacerbation, MALT1 was negatively related to forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) (p = 0.024) and FEV1% predicted (p = 0.002), but positively linked with global initiative for chronic obstructive lung disease stage (p = 0.005).Conclusion: Blood MALT1 reflects increased acute exacerbation risk and inflammation in elderly COPD patients.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"513-521"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364060/pdf/","citationCount":"0","resultStr":"{\"title\":\"Blood MALT1 reflects acute exacerbation risk and inflammation in elderly chronic obstructive pulmonary disease patients.\",\"authors\":\"Cui Liu, Jinsong Zhu, Lei Zhao, Guanying Li, Jiawei Sun, Shengli Zhang, Xijun Liang\",\"doi\":\"10.1080/17520363.2024.2347199\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: This study intended to investigate the ability of blood MALT1 to estimate acute exacerbation risk in elderly chronic obstructive pulmonary disease (COPD) patients.Methods: Blood MALT1 was detected in 176 elderly COPD patients (aged more than 60 years).Results: MALT1 was elevated in patients with COPD acute exacerbation versus patients with stable COPD (p < 0.001). In patients with COPD acute exacerbation, MALT1 was negatively related to forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) (p = 0.024) and FEV1% predicted (p = 0.002), but positively linked with global initiative for chronic obstructive lung disease stage (p = 0.005).Conclusion: Blood MALT1 reflects increased acute exacerbation risk and inflammation in elderly COPD patients.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"513-521\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364060/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2024.2347199\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2347199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究旨在探讨血液 MALT1 对老年慢性阻塞性肺病（COPD）患者急性加重风险的估计能力。方法对 176 名老年慢性阻塞性肺病患者（年龄超过 60 岁）的血液 MALT1 进行检测。结果MALT1与1秒用力呼气容积（FEV1）/用力肺活量（FVC）（p = 0.024）和预测FEV1%（p = 0.002）呈负相关，但与慢性阻塞性肺病全球倡议阶段（p = 0.005）呈正相关。结论血液 MALT1 反映了老年慢性阻塞性肺疾病患者急性加重风险和炎症的增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Blood MALT1 reflects acute exacerbation risk and inflammation in elderly chronic obstructive pulmonary disease patients.

Aim: This study intended to investigate the ability of blood MALT1 to estimate acute exacerbation risk in elderly chronic obstructive pulmonary disease (COPD) patients.Methods: Blood MALT1 was detected in 176 elderly COPD patients (aged more than 60 years).Results: MALT1 was elevated in patients with COPD acute exacerbation versus patients with stable COPD (p < 0.001). In patients with COPD acute exacerbation, MALT1 was negatively related to forced expiratory volume in 1 s (FEV₁)/forced vital capacity (FVC) (p = 0.024) and FEV₁% predicted (p = 0.002), but positively linked with global initiative for chronic obstructive lung disease stage (p = 0.005).Conclusion: Blood MALT1 reflects increased acute exacerbation risk and inflammation in elderly COPD patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.